Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRESCO-2 trial of fruquintinib plus best supportive care in refractory metastatic colorectal cancer
jRCT2041200099Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fruquintinib in colorectal adenocarcinoma and colorectal cancer (CRC) (3 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Overall survival and Safety and tolerability. Started Nov 2020; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2041200099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200099.